Pre-Conference Workshop Day - Tuesday, March 22

 10AM – 1PM | Workshop A

Implementation of Continuous Processing in Synthetic Molecules

Building a Business Case for Continuous Manufacturing in Your Organization

• A Strategy for engaging stakeholders for investment in new technologies

• Identifying the Spearhead application and calculating the NPV for the application

• Articulating the expected ROI

Internal Capability Building for Continuous Manufacturing Process Development

• A few differences in CM process development compared to batch

• People requirement: Given the highlighted differences, what skills are required to develop CM process effectively?

• Approaches for hiring top continuous talent

• Approaches to organizing the team and managing a CM development portfolio

Dan Griffin Amgen

Daniel Griffin

Principal Engineer

Amgen

Benjamin Rizkin AbbVie

Benjamin Rizkin

 Senior Scientist

AbbVie

Eric Moschetta AbbVie

Eric Moschetta

Senior Scientist II

AbbVie

1:30PM - 4:30 PM | Workshop B:
Implementation of Continuous Processing in Biologics

How has Continuous Processing Shaped Biologic Drug Development?

• Review of Progress, Opportunities and Challenges in the Industry to date

• Why are FDA approved CM drugs focussed on small molecules? Is the breakthrough for biologics on its way?

• What are the business case drivers for adopting continuous bioprocessing? What is the opportunity cost of not adopting?

Building Capabilities for Industrial Continuous Bioprocessing

• Capability Building for Continuous Processing in Pharma: experiences from buildout and implementation

• How does continuous processing fit into a wider industrialization strategy?

• What teams need to work together to drive change: where is best to implement from early phase to commercial development?

jeff odum high res

Jeff Odum

Instructor

The Parental Drug Association

Site Visit to Continuus Pharmaceuticals 

Site Visit 1 - 9:30am | Site Visit 2 - 1:30pm

JOIN YOUR CCP COMMUNITY ON A TRIP TO CONTINUUS PHARMACEUTICALS PILOT LINE & MAIN FACILITY

CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT And Novartis on continuous manufacturing, who specialize in end-to end integrated continuous manufacturing (ICM), with the application of novel process technologies that enable rapid production of pharmaceuticals at significantly reduced costs and better quality. Hosted by CONTINUUS Pharmaceuticals, attendees will be able to visit BOTH their pilot line and main facility, to see first-hand the state-of the- art and fully integrated continuous manufacturing facility.

The site visit will enable you to understand the potential and opportunities in ICM to improve affordability and accessibility of pharmaceuticals on a global scale and evaluate investment, implementation and build-out of commercial ICM plants. With a recent $69.3 million U.S. government grant contract to facilitate domestic production of three vital medicines, find out how CONTINUUS are enabling GMP end-to-end integrated continuous manufacturing.

We’ll provide transportation to and from the conference venue to CONTINUUS Pharmaceuticals. There will be two scheduled visit groups, and places are strictly limited, to ensure social distancing and best learning experience for attendees*.

*As places are very limited, preference will be given to those attending the implementation workshops or focus morning. Please see registration page for charges.

 

Must Be Bought Together With a Conference Pass. Limited Spaced Available -            Get Tickets Here